Credit Suisse who are very well known and respected have written a report on Admedus. They know the TAVR space very well and were the ones who came out and said the TAVR market would double when the FDA approved TAVR for lower risk patients.
https://cdn.admedus.com/2020/02/02075029/2020-Week-of-Pre-Releases-and-Meetings-Point-to-Solid-Fundamentals-and-Healthy-Innovation-1-17-20.pdf
Credit Suisse report on Admedus
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |